أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops - excipient ingredients: sodium hydroxide; benzalkonium chloride; citric acid monohydrate; hydrochloric acid; dibasic sodium phosphate heptahydrate; purified water; sodium chloride - bimatoprost eye drops are indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - ketotifen fumarate, quantity: 0.345 mg/ml (equivalent: ketotifen fumarate, qty 0.25 mg/ml; equivalent: ketotifen, qty 0.25 mg/ml) - eye drops, solution - excipient ingredients: glycerol; water for injections; sodium hydroxide - the symptomatic short term treatment of seasonal allergic conjuctivitis in adults and children 3 years or older.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciprofloxacin hydrochloride, quantity: 3.5 mg/ml (equivalent: ciprofloxacin, qty 3 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; mannitol; sodium hydroxide; purified water; hydrochloric acid; disodium edetate; glacial acetic acid; sodium acetate - treatment of bacterial keratitis (infected corneal ulcers) and severe bacterial conjunctivitis caused by organisms susceptible to ciprofloxacin in adults and children 12 months of age or older.

مالطا - الإنجليزية - Medicines Authority

uni-pharma kleon tsetis pharmaceutical laboratories s.a. 14th km national road athens - lamia 1, gr-145 64 kifissia, greece - eye drops, solution - prednisolone 5 mg/ml - ophthalmologicals

مالطا - الإنجليزية - Medicines Authority

rayner pharmaceuticals ltd 10 dominion way, worthing, west sussex, bn14 8aq,, united kingdom - dexamethasone phosphate - eye drops, solution - dexamethasone phosphate 1 mg/ml - ophthalmologicals

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - hamamelis water; naphazoline hydrochloride - eye drops, solution - 12.5 %w/v + 0.01 percent weight/volume - sympathomimetics used as decongestants; naphazoline, combinations

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - travoprost, quantity: 40 microgram/ml - eye drops, solution - excipient ingredients: boric acid; ethoxylated hydrogenated castor oil; polyquaternium-1; sodium hydroxide; mannitol; hydrochloric acid; propylene glycol; purified water; sodium chloride - travatan eye drops are indicated to decrease elevated intraocular pressure in: - ocular hypertension. - open-angle glaucoma. travatan eye drops may be used: - as first line monotherapy. - as adjunctive therapy.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - latanoprost, quantity: 0.05 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate; benzalkonium chloride; water for injections; monobasic sodium phosphate monohydrate - reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride, quantity: 5.6 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium hydroxide; sodium chloride; hydrochloric acid; disodium edetate; purified water - indications as at 23 march 1999: betoptic 0.5% have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angular glaucoma. betoptic eye drops 0.5% may be used alone or in combination with other iop-lowering medication.